Cynapsus Therapeutics Inc. (CYNAF: OTCQX International) | Cynapsus Therapeutics Announces Uplisting to the Toronto Stock Exchange’s Senior Equity Market


Cynapsus Therapeutics Announces Uplisting to the Toronto Stock Exchange’s Senior Equity Market

Nov 25, 2014

OTC Disclosure News Service

Cynapsus Therapeutics Inc. (TSX-V:CTH) (OTCQX:CYNAF), a specialty
pharmaceutical company focused on Parkinson’s disease, today announced
that its common shares will commence trading on the Toronto Stock
Exchange (TSX) as of the opening of trading on Friday, November 28,
2014. The Company’s common shares will continue to trade under the
symbol “CTH,” with its common shares to cease trading on the TSX Venture
Exchange concurrent with the commencement of trading on the TSX.

This change does not affect the trading of the Company’s shares on the
OTCQX International in the United States.

“The Toronto Stock Exchange is among the global leaders in listing
public companies and is the premier exchange in Canada,” stated Anthony
Giovinazzo, Cynapsus’ President and CEO. “Uplisting the trading of our
shares to the TSX is an important milestone for Cynapsus as it provides
us with broader market recognition that is reflective of the Company’s
progress and potential.”

About Cynapsus

Cynapsus is a specialty pharmaceutical company developing a sublingual
thin filmstrip for the acute rescue of OFF motor symptoms of Parkinson’s
disease. Cynapsus’ drug candidate, APL-130277, is an easy-to-use,
fast-acting formulation of apomorphine, which is the only approved drug
(in the United States, Europe, Japan and other countries) to rescue
patients from OFF episodes. Cynapsus is focused on maximizing the value
of APL-130277 by completing pivotal studies in advance of a 505(b)(2)
New Drug Application (NDA) expected to be submitted in 2016.

More than 1 million people in the U.S. and an estimated 4 to 6 million
people globally suffer from Parkinson’s disease. Parkinson’s disease is
a chronic and progressive neurodegenerative disease that impacts motor
activity, and its prevalence is increasing with the aging of the
population. OFF episodes are a complication of Parkinson’s disease that
leave patients rigid and unable to move and communicate. An estimated
one quarter to one half of all people with Parkinson’s disease whose
symptoms are otherwise managed with ongoing drug therapy experience OFF
episodes at least once daily and up to six times daily, with each
episode lasting between 30 and 120 minutes.

More information about Cynapsus (TSX-V:CTH) (OTCQX:CYNAF) is available
and at the System for Electronic Document Analysis and Retrieval (SEDAR)

Forward Looking Statements

This announcement contains “forward-looking statements” within the
meaning of applicable securities laws. Generally, these forward-looking
statements can be identified by the use of forward-looking terminology
such as “plans”, “expects” or “does not expect”, “is expected”,
“budget”, “scheduled”, “estimates”, “forecasts”, “intends”,
“anticipates” or “does not anticipate”, or “believes” or variations of
such words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will be taken”, “occur” or “be
achieved”. Forward-looking statements are subject to known and unknown
risks, uncertainties and other factors that may cause the actual
results, level of activity, performance or achievements of Cynapsus to
be materially different from those expressed or implied by such
forward-looking statements, including but not limited to those risks and
uncertainties relating to Cynapsus’ business disclosed under the heading
“Risk Factors” in its March 26, 2014, Annual Information Form and its
other filings with the various Canadian securities regulators which are
available online at
Although Cynapsus has attempted to identify important factors that could
cause actual results to differ materially from those contained in
forward-looking statements, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those anticipated
in such statements. Accordingly, readers should not place undue reliance
on forward-looking statements. Cynapsus does not undertake to update any
forward-looking statements, except in accordance with applicable
securities laws.

Neither the TSX Venture Exchange nor the OTCQX International has
approved or disapproved of the contents of this press release.

Copyright © 2014 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply